SCHEMBL800740

SCHEMBL800740

O=C(O)/C(=C/Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.61
CYP2C9 P11712 1/20 0.61
CES1 P23141 2/20 0.50
CES2 O00748 1/20 0.50
AKR1B1 P15121 1/20 0.50
CTBP2 P56545 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
MAOB P27338 1/20 0.43
GRIK1 P39086 1/20 0.42
FNTA P49354 1/20 0.42
FNTB P49356 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
EPHX2 P34913 1/20 0.41
PAM P19021 2/20 0.40
TOP1 P11387 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propylene Glycol SCHEMBL28558577 0.88 CYP3A4 (0.50) CYP3A4CYP2C9CES1CES2AKR1B1
SCHEMBL4881810 0.85 CYP3A4 (0.49) CYP3A4CYP2C9CES1CES2AKR1B1
SCHEMBL6647228 0.85 CYP3A4 (0.49) CYP3A4CYP2C9CES1CES2AKR1B1
SCHEMBL5727501 0.82 CYP2C9 (0.46) CYP3A4CYP2C9CES1CES2AKR1B1
SCHEMBL165759 0.82 TSHR (0.46) CYP3A4CYP2C9CES1CES2AKR1B1
SCHEMBL10705265 0.82 CYP2C9 (0.46) CYP3A4CYP2C9CES1CES2AKR1B1
SCHEMBL2192019 0.82 CYP3A4 (0.59) CYP3A4CYP2C9CES1CES2AKR1B1
SCHEMBL800101 0.82 CYP3A4 (0.59) CYP3A4CYP2C9CES1CES2AKR1B1
SCHEMBL7336694 0.82 CYP3A4 (0.59) CYP3A4CYP2C9CES1CES2AKR1B1
SCHEMBL27285244 0.82 CYP3A4 (0.59) CYP3A4CYP2C9CES1CES2AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS MEIJI SEIKA KAISHA (JP) 2016-06-02 US disclosed
US-9260375-B2 Metallo-β-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2016-02-16 US disclosed
US-9115079-B2 NDM inhibitor MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-08-25 US disclosed
US-20140221330-A1 NDM INHIBITOR MEIJI SEIKA PHARMA CO., LTD. (JP) 2014-08-07 US disclosed
US-20120071457-A1 METALLO-BETA-LACTAMASE INHIBITORS CHIKAUCHI KEN (JP) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071457-A1 METALLO-BETA-LACTAMASE INHIBITORS ME1, MGAM, GAA CYP3A4 1281/4885CYP2C9 864/4885CES1 206/4885
US-20140221330-A1 NDM INHIBITOR MGAM, NQO1, NQO2 CYP3A4 1708/4885CYP2C9 1554/4885CES1 481/4885
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS ME1, MGAM, MANBA CYP3A4 1259/4885CYP2C9 847/4885CES1 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.